Methods to increase the effectiveness of cancer therapy with FOLR1

An anti-receptor 1 Folate (FOLR1) or an anti-FOLR1 immunoconjugate for use in cancer therapy in a subject antibody, is detected increased expression of the gene or FOLR1 protein in the sample of cancer said subject using a detection method different staining intensity or uniformity of staining in a sample expressing cancer FOLR1 as compared with the staining intensity or uniformity of staining in one or more reference samples, in the effectiveness of cancer therapy with an anti-FOLR1 antibody or anti-FOLR1 immunoconjugate is increased thereby; wherein the anti-FOLR1 antibody for use in cancer therapy comprising: (i) a variable domain of heavy chain comprising the amino acid sequence of SEQ ID NO: 3 (huMov19 VHC) and a variable light chain domain that it comprises the amino acid sequence of SEQ ID NO: 4 (huMov19 vLCv1.00) or (ii) a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO: 3 (huMov19 VHC) and a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 5 (huMov19 vLCv1.60); and wherein the anti-FOLR1 immunoconjugate for use in cancer therapy comprising an anti- FOLR1, a connector and a cytotoxin, wherein the anti-anti-FOLR1 immunoconjugate FOLR1 antibody comprises: (i) a variable domain heavy chain comprising the amino acid sequence of SEQ ID NO: 3 (huMov19 VHC) and a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 4 (huMov19 vLCv1.00) or (ii) a domain variable heavy chain comprising the amino acid sequence of SEQ ID NO: 3 (huMov19 VHC) and a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 5 (huMov19 vLCv1.60).